GDNF and amyotrophic lateral sclerosis: Although edaravone, one of only two FDA-approved therapeutics for ALS, has been shown to increase RET, GDNF and GFRα1 protein levels [24], enhancing GDNF signalling in ALS has so far either induced adverse effects [27] or failed to translate to significant clinical improvements [26].